The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma

Genes Chromosomes and Cancer

Volumn 52, Issue 8, 2013, Pages 764-774

  Bertrand, P ^a   Maingonnat, C ^a   Penther, D ^a   Guney, S ^a   Ruminy, P ^a   Picquenot, J M ^a   Mareschal, S ^a   Alcantara, M ^a   Bouzelfen, A ^a   Dubois, S ^a   Figeac, M ^b   Bastard, C ^a   Tilly, H ^a   Jardin, F ^a  

^a UNIVERSITY OF ROUEN   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD70 ANTIGEN; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; DNA MODIFICATION; DOWN REGULATION; EPIGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MULTIPLEX POLYMERASE CHAIN REACTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC MUTATION; SURVIVAL TIME;

ANTIGENS, CD70; CHROMOSOME BREAKPOINTS; CHROMOSOME DELETION; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS;

EID: 84879256481     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22072     Document Type: Article

References (69)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
2. Arens R, Tesselaar K, Baars PA, van Schijndel GM, Hendriks J, Pals ST, Krimpenfort P, Borst J, Van Oers MH, van Lier RA. 2001. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 15:801-812.
3. Arens R, Nolte MA, Tesselaar K, Heemskerk B, Reedquist KA, van Lier RA, Van Oers MH. 2004a. Signaling through CD70 regulates B cell activation and IgG production. J Immunol 173:3901-3908.
4. Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, Van Oers MH. 2004b. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med 199:1595-1605.
5. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors J M, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A. 2005. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106:3183-3190.
6. Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ. 1990. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst 82:501-509.
7. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist soc B 57:239-300.
8. Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel MN, Ruminy P, Picquenot J M, Tilly H. 2007. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia 21:515-523.
9. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C, Widaa S, Hinton J, Fahey C, Fu B, Swamy S, Dalgliesh GL, Teh BT, Deloukas P, Yang F, Campbell PJ, Futreal PA, Stratton MR. 2010. Signatures of mutation and selection in the cancer genome. Nature 463:893-898.
10. Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. 1994. The cloning of CD70 and its identification as the ligand for CD27. J Immunol 152:1756-1761.
11. Boyd RS, Jukes-Jones R, Walewska R, Brown D, Dyer MJ, Cain K. 2009. Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics 8:1501-1515.
12. Brown GR, Meek K, Nishioka Y, Thiele DL. 1995. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes. J Immunol 154:3686-3695.
13. Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M. 2002. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 20:218-226.
14. Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M, Tannenbaum C, Barnett G, Finke JH. 2005. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res 65:5428-5438.
15. Chen W, Houldsworth J, Olshen AB, Nanjangud G, Chaganti S, Venkatraman ES, Halaas J, Teruya-Feldstein J, Zelenetz AD, Chaganti RS. 2006. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 107:2477-2485.
16. Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. 2012. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 72:3664-3676.
17. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L. 2009. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459:717-721.
18. Cormary C, Gonzalez R, Faye JC, Favre G, Tilkin-Mariame AF. 2004. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther 11:497-507.
19. Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, Favre G, Lotze MT, Robbins PD. 1998. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther 5:163-175.
20. De Colvenaer V, Taveirne S, Hamann J, de Bruin AM, De SM, Taghon T, Vandekerckhove B, Plum J, van LR, Leclercq G. 2010. Continuous CD27 triggering in vivo strongly reduces NK cell numbers. Eur J Immunol 40:1107-1117.
21. Diegmann J, Junker K, Gerstmayer B, Bosio A, Hindermann W, Rosenhahn J, von Eggeling F. 2005. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 41:1794-1801.
22. Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B. 2000. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther 7:1543-1556.
23. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, Tutt AL, Al-Shamkhani A, Glennie MJ. 2007. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109:4810-4815.
24. Garcia P, De Heredia AB, Bellon T, Carpio E, Llano M, Caparros E, Aparicio P, Lopez-Botet M. 2004. Signalling via CD70, a member of the TNF family, regulates T cell functions. J Leukoc Biol 76:263-270.
25. Giefing M, Arnemann J, Martin-Subero JI, Nielander I, Bug S, Hartmann S, Arnold N, Tiacci E, Frank M, Hansmann ML, Kuppers R, Siebert R. 2008. Identification of candidate tumour suppressor gene loci for Hodgkin and Reed-Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. Br J Haematol 142:916-924.
26. Glouchkova L, Ackermann B, Zibert A, Meisel R, Siepermann M, Janka-Schaub GE, Goebel U, Troeger A, Dilloo D. 2009. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia. J Immunol 182:718-725.
27. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, Tough TW, Schoenborn MA, Davis-Smith T, Hennen K. 1993a. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73:447-456.
28. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, Tough TW, Schoenborn MA, Davis-Smith T, Hennen K, Falk B, Cosman D, Baker E, Sutherland GR, Grabstein KH, Farrah T, Giri JG, Beckmann MP. 1993b. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73:447-456.
29. Guney S, Bertrand P, Jardin F, Ruminy P, Kerckaert JP, Tilly H, Bastard C. 2011. Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas. Genes Chromosomes Cancer 50:715-725.
30. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 1:433-440.
31. Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. 1995. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 154:2612-2623.
32. Hishima T, Fukayama M, Hayashi Y, Fujii T, Ooba T, Funata N, Koike M. 2000. CD70 expression in thymic carcinoma. Am J Surg Pathol 24:742-746.
33. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, Lynch JC, Armitage JO, Warnke RA, Alizadeh AA, Lossos IS, Levy R, Chan WC. 2002. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285-2290.
34. Jardin F, Ruminy P, Kerckaert JP, Parmentier F, Picquenot JM, Quief S, Villenet C, Buchonnet G, Tosi M, Frebourg T, Bastard C, Tilly H. 2008. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas. Haematologica 93:543-550.
35. Jardin F, Picquenot JM, Parmentier F, Ruminy P, Cornic M, Penther D, Bertrand P, Lanic H, Cassuto O, Humbrecht C, Lemasle E, Wautier A, Bastard C, Tilly H. 2009a. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: Clinicopathological relevance and prognosis value. Br J Haematol 146:607-618.
36. Jardin F, Callanan M, Penther D, Ruminy P, Troussard X, Kerckaert JP, Figeac M, Parmentier F, Rainville V, Vaida I, Bertrand P, Duval AB, Picquenot JM, Chaperot L, Marolleau JP, Plumas J, Tilly H, Bastard C. 2009b. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia 23:698-707.
37. Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, Thieblemont C, Gisselbrecht C, de Reynies A, Coiffier B, Haioun C, Leroy K. 2010. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 116:1092-1104.
38. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3:83-90.
39. Lanic H, Mareschal S, Mechken F, Picquenot JM, Cornic M, Maingonnat C, Bertrand P, Clatot F, Bohers E, Stamatoullas A, Lepretre S, Rainville V, Ruminy P, Bastard C, Tilly H, Becker S, Vera P, Jardin F. 2012. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. Leuk Lymphoma 53:34-42.
40. Lens SM, Drillenburg P, den Drijver BF, van Schijndel G, Pals ST, van Lier RA, Van Oers MH. 1999. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 106:491-503.
41. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. 2008. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105:13520-13525.
42. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
43. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernandez-Lemus E, Schwarz C, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub TR. 2012. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 109:3879-3884.
44. Lorenz MG, Kantor JA, Schlom J, Hodge JW. 1999. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 10:1095-1103.
45. Lu Q, Wu A, Richardson BC. 2005. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 174:6212-6219.
46. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL. 2007. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109:1185-1192.
47. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, Grewal IS, Law CL. 2008. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 14:7763-7772.
48. Miller J, Eisele G, Tabatabai G, Aulwurm S, von Kürthy G, Stitz L, Roth P, Weller M. 2010. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. J Neurosurg 113:280-285.
49. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal CP, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. 2005. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861.
50. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA. 2011. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298-303.
51. Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM. 1998. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response. J Immunother 21:225-236.
52. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R. 2011. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43:830-837.
53. Penaloza-Macmaster P, Rasheed AU, Iyer SS, Yagita H, Blazar BR, Ahmed R. 2011. Opposing Effects of CD70 Costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice. J Virol 85:6168-6174.
54. Ranheim EA, Cantwell MJ, Kipps TJ. 1995. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85:3556-3565.
55. Rowley TF, Al-Shamkhani A. 2004. Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J Immunol 172:6039-6046.
56. Ruminy P, Jardin F, Picquenot JM, Gaulard P, Parmentier F, Buchonnet G, Maisonneuve C, Tilly H, Bastard C. 2006. Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology. Oncogene 25:4947-4954.
57. Ruminy P, Etancelin P, Couronne L, Parmentier F, Rainville V, Mareschal S, Bohers E, Burgot C, Cornic M, Bertrand P, Lenormand B, Picquenot JM, Jardin F, Tilly H, Bastard C. 2011. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. Leukemia 25:681-688.
58. Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, Kim KM, Nesterova A, Anderson M, McEarchern JA, Law CL, Smith LM. 2010. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer 103:676-684.
59. Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC, Vose JM, Chigrinova E, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Lambotte O, Uccella S, Pinotti G, Pruneri G, Martinelli G, Young KH, Tibiletti MG, Rinaldi A, Zucca E, Kwee I, Bertoni F. 2010. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol 151:221-231.
60. Scholtysik R, Nagel I, Kreuz M, Vater I, Giefing M, Schwaenen C, Wessendorf S, Trumper L, Loeffler M, Siebert R, Kuppers R. 2012. Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. Int J Cancer 131:E830-E835.
61. Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S. 2011. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117:4304-4314.
62. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardifman JW, Eds. World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon 2008.
63. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, Okamoto M, Morishima Y, Nakamura S, Seto M. 2005. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106:1770-1777.
64. Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, Van Oers MH, van Lier RA. 2003. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol 4:49-54.
65. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M. 2002. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62:2592-2599.
66. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. 2007. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 110:2537-2544.
67. Yoshino K, Kishibe K, Nagato T, Ueda S, Komabayashi Y, Takahara M, Harabuchi Y. 2013. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27. Br J Haematol 160:331-342.
68. Yu SE, Park SH, Jang YK. 2010. Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer. Mol Cells 29:217-221.
69. Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E, Kere J, Mannila H, Franssila K, Knuutila S. 2002. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 119:905-915.